Document |
Document Title |
WO/2024/027116A1 |
Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4, Q, n, and A are described herein, which are useful as Lp-PLA2 inhibitors, pharmaceutical compositions comprising the ...
|
WO/2024/028458A2 |
This invention relates to compounds and salts thereof that are muscarinic receptor agonists and which are useful in the treatment of muscarinic receptor mediated diseases. Also provided are crystalline forms of the compounds and salts th...
|
WO/2024/027845A1 |
Provided is the following compound (I) or a pharmaceutically acceptable salt, ester, optical isomer, stereoisomer, polymorph, solvate, N-oxide, isotopically-labeled compound, metabolite, chelate, complex, inclusion complex, or prodrug th...
|
WO/2024/031030A2 |
A method of treatment of mental disorder of a subject includes the steps of: normalizing an expression of both DRD1 and DRD5, which belong to DRDl-like family, of the subject to a preset standard level. The DRD1/5 level and expression ca...
|
WO/2024/029620A1 |
The present invention relates to a cerebral blood flow augmenter that contains isomaltulose as an active ingredient.
|
WO/2024/029599A1 |
Provided is a pharmaceutical composition containing, as an active ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methox
yphenyl)pyrrolidine-3-yl]carbonyl}-4-(methoxymethyl)pyrrolid
ine-3-yl]-5-(trifluoromethyl)phenyl}p...
|
WO/2024/025042A1 |
A composition comprising AAV2-ANKS1A recombinant virus for treating Alzheimer's disease is provided. Specifically, it is identified that ANKS1A (ankyrin repeat and sterile alpha motif domain containing 1A) protein binds to an LRP1 recept...
|
WO/2023/010078A9 |
The present invention relates to compounds of Formula (Ia), pharmaceutically acceptable salts of compounds of Formula (Ia), and pharmaceutical compositions thereof that modulate the activity of the muscarinic acetylcholine receptor M4. C...
|
WO/2024/026350A1 |
Compounds having opioid characteristics are provided that can be used for various therapeutic methods including the treatment of pain and opioid use disorders, and compounds having opioid antagonist properties that can be used to treat o...
|
WO/2024/022528A1 |
Disclosed are compounds having general formula I, a method for preparing same, a pharmaceutical composition thereof, and use thereof. Specifically, the present invention provides a compound having a structure represented by general formu...
|
WO/2024/024985A1 |
Provided is a drug for treating Alzheimer's disease, the drug enabling retention of cognitive function amelioration and nerve quality improvement for a specific time even after treatment ends. This drug for causal treatment of Alzheime...
|
WO/2024/023128A1 |
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, composition including the compounds and methods of using the compounds.
|
WO/2024/021626A1 |
Disclosed in the present invention are pramipexole xinafoate and a sustained-release pharmaceutical preparation thereof. In the present invention, after pramipexole is prepared into pramipexole xinafoate, the solubility of salts of prami...
|
WO/2024/023281A1 |
The invention concerns a novel and innovative composition for the treatment of neuropathic pain (NP). Specifically, the invention concerns HfO2 nanoparticles and/or aggregates of HfO2 nanoparticles, a composition comprising said nanopart...
|
WO/2024/020953A1 |
Provided are a steroid compound for treating a central nervous system disease, a method for preparing same, and use and a pharmaceutical composition thereof. The steroid compound has a 9β,10α structure and has the following structural ...
|
WO/2024/023287A1 |
The present invention relates to a compound of general formula (I). The invention further relates to the compounds of the invention as neuroprotective and/or neurorestorative agents, in particular for use in the treatment of neurological...
|
WO/2024/026306A1 |
The present invention provides methods for targeting an agent to the peripheral nervous system of a subject. In these methods, targeting is achieved by conjugating the agent to an antibody that can transport conjugated cargo across the b...
|
WO/2024/026337A1 |
This invention relates to crystalline solvated forms of Compound (1) and pharmaceutical compositions thereof. Also disclosed herein are methods of making crystalline solvated solid forms of Compound (1), and methods of using the crystall...
|
WO/2024/024961A1 |
The present invention relates to a therapeutic agent and/or prophylactic agent for central nervous system diseases involving abnormal aggregates of brain proteins. The therapeutic agent and/or prophylactic agent contains, as active ingre...
|
WO/2024/024565A1 |
The present invention addresses the problem of providing an agent that suppresses cell aging and a drug that prevents or treats diseases and the like caused by cell aging. More specifically, the present invention is a cell aging suppress...
|
WO/2024/026420A1 |
Systems and methods for the identification of auto-antibodies associated with central nervous system or psychiatric disease or disorders. Also disclosed herein are methods of treating central nervous system or psychiatric disease or diso...
|
WO/2024/025817A1 |
Described herein are solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrid
o[3,4-f][1,4]oxazepine-9-carbonitrile, the process of preparing the forms, pharmaceutical compositions comprising same, and methods of use t...
|
WO/2024/023274A2 |
The present invention relates to a composition comprising harmine and (i) an uronic acid or (ii) a carboxylic acid and a monosaccharide, to a salt of harmine and uronic acid, to a kit of parts comprising (a) the composition or the salt o...
|
WO/2024/021383A1 |
The present invention relates to the field of disease treatment. In particular, the present invention provides a gp96 protein and use of a gp96 protein-constructed fusion protein in treating amyotrophic lateral sclerosis. In addition, th...
|
WO/2024/021625A1 |
A crystal form A of pramipexole xinafoate salt ((S)-(-)-2-amino-6-(propylamino)-4,5,6,7-tetrahydrobenzothia
zole bis(1-hydroxynaphthoate) and a preparation method for the crystal form A. The structural formula of the pramipexole xinafoat...
|
WO/2024/023284A1 |
The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof. The invention further relates to the use of the compounds of the invention as neuroprotective and/or neurore...
|
WO/2024/025955A1 |
The present invention relates to a method of treating cognitive impairment in a patient with schizophrenia who is being treated with antipsychotic treatment in need thereof by administering Compound (I), a stimulator of soluble guanylate...
|
WO/2024/022468A1 |
The present invention belongs to the technical field of medicines. Disclosed are use of rhamnose in preparing a medicament for treating or preventing neurodegenerative diseases, a pharmaceutical composition, and use thereof. The present ...
|
WO/2024/026463A1 |
The present inventive concept is directed to compositions that allow nasal delivery of an active compound. Particularly, the disclosed compositions include dimethyl sulfoxide (DMSO). one or more active compounds, water, and optionally a ...
|
WO/2024/023367A1 |
An aqueous oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine as active ingredient and a standard amino acid as stabilizer.
|
WO/2024/026471A1 |
The present disclosure is generally directed to antigen-binding domains that specifically bind to human CD98 heavy chain (CD98hc) and their use in transport across the blood brain barrier (BBB).
|
WO/2024/020696A1 |
The present application includes an enantiomerically pure compound of Formula (R)-I or a salt and/or solvate thereof (R)-I. Also included are compositions of the enantiomerically pure compound of Formula (R)-I as well as methods of using...
|
WO/2024/025809A1 |
The present disclosure describes delivery of nucleic acids to the central nervous system using extracellular vesicles, and in particular red blood cell extracellular vesicles.
|
WO/2024/021826A1 |
Disclosed are a pharmaceutical composition for treating cancerous pain and a preparation method therefor. The pharmaceutical composition is prepared from the following ingredients: 15-20 parts by weight of unprocessed Aconiti Lateralis R...
|
WO/2024/021431A1 |
Provided is use of a gene delivery system in delivering a gene from the brain to the spinal cord or in preparing a reagent for delivering a gene from the brain to the spinal cord, wherein the gene delivery system comprises an adeno-assoc...
|
WO/2024/025953A2 |
Disclosed are methods for treating a neuromuscular disorder, muscle disorder, heart disease, pulmonary fibrosis, liver disease, inflammatory bowel disease, or cancer. Also disclosed is a method of enhancing cancer immunotherapy.
|
WO/2024/020637A1 |
There is provided a method of treating or improving a symptom of a neuronal injury in a subject, the method comprising administering to the subject a therapeutically effective amount of an acellular allogenic preparation with exosomes (U...
|
WO/2024/025536A1 |
We used a powerful longitudinal within-subject design in individuals with psychiatric disorders to discover blood gene expression change between self-reported low anxiety and high anxiety states. We prioritized the list of candidate biom...
|
WO/2024/025193A1 |
Neural stem cells cultured in the cultivation composition of the present invention, the cultivation composition including a substrate with controlled mechanical strength (for example, hydrogel), are excellent in cell adhesion and surviva...
|
WO/2024/023261A1 |
Present invention relates to dexmedetomidine or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of a sleep disorder in a subject, wherein dexmedetomidine or its salt is to be administered to a subject vi...
|
WO/2024/026061A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject i...
|
WO/2024/020843A1 |
The present invention provides use of citrulline or a pharmaceutically acceptable salt thereof in the preparation of a medicament, a method for improving the activity of matrix metalloproteinase 7, a method for up-regulating the expressi...
|
WO/2024/023282A1 |
The invention concerns a novel and innovative composition for the treatment of neuropathic pain (NP). Specifically, the invention concerns nanoparticles and/or aggregates of nanoparticles, a composition comprising said nanoparticles and/...
|
WO/2024/022546A1 |
The present invention provides 2-arylbenzothiazole derivatives of general formula I, or pharmaceutically acceptable salts thereof with alkali metals, ammonia or amines, or their addition salts with acids, wherein R1 is selected from NHCO...
|
WO/2024/022009A1 |
The present disclosure provides a nanoprotein degradation tool, use thereof, and a preparation method therefor. The nanoprotein degradation tool comprises: one or a plurality of combinations of a first degradation tool, a second degradat...
|
WO/2024/021050A1 |
Disclosed are a levetiracetam sustained-release formulation and a preparation method therefor. The sustained-release formulation comprises a core, a sustained-release layer, and a modification layer sequentially from inside to outside, a...
|
WO/2024/024865A1 |
The present disclosure provides an oral pharmaceutical composition containing levodopa and carbidopa as pharmaceutical active ingredients.
|
WO/2024/026368A1 |
This disclosure is drawn to pyridine derivatives, compositions thereof, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological disorders.
|
WO/2024/023441A1 |
Disclosed is a pharmaceutical composition for use in the treatment of post-traumatic stress syndrome in human beings, comprising: - cyproheptadine, which is selected as a compound having an antagonistic activity against 5-HT2 serotonin r...
|
WO/2024/025961A1 |
The use of cannabis and/or its parts (e.g., cannabinoids, CBD, THC, cannabidiol, hemp) to treat or reduce the effects caused by exposure to glyphosate, glyphosate derivatives, glyphosate disorders, and/or glyphosate toxicity in the human...
|